Forward to: R&D Team

Genomics & CRISPR Tracking
Workflows

Ten agent workflows for the R&D Team — gene therapy developer monitoring, CRISPR platform tracking, genomics tool assessment, next-generation sequencing intelligence, gene editing IP landscape, cell therapy manufacturing, base/prime editing advances, epigenetic therapy tracking, spatial genomics innovation, and R&D strategy dashboard — enabling data-driven genomics decisions powered by comprehensive domain intelligence.

1Gene Therapy Developer Monitoring

AI agent monitors gene therapy company domains to track vector development, clinical programs, manufacturing capabilities, and regulatory pathways across in vivo and ex vivo gene therapy approaches.

1
Track Gene Therapy Landscape
/products/investors/pressOpenPageRank
GENE THERAPY LANDSCAPE — 280 COMPANIES TRACKED ════════════════════════════════════════════════════════ bluebirdbio.com — Ex Vivo Gene Therapy /products: Lyfgenia (sickle cell) + Zynteglo (beta-thal) /investors: Revenue $38M — slower than expected uptake /press: VOC crisis reduction: 88% in treated patients SIGNAL: Efficacy proven but commercial model struggling sarepta.com — AAV Gene Therapy /products: Elevidys — micro-dystrophin for DMD /investors: Confirmatory trial ongoing — mixed signal /careers: +40% manufacturing positions posted SIGNAL: Manufacturing scale-up — preparing for broader launch ultragenyx.com — AAV Platform /products: DTX401 (GSDIa) — liver-directed gene therapy /press: Phase 3 initiated — first liver gene therapy pivotal SIGNAL: Liver gene therapy advancing — monitor competitors

2CRISPR Platform Intelligence

AI agent monitors CRISPR technology company domains to track platform developments, new editing modalities, delivery innovations, and clinical applications of gene editing technologies.

1
Monitor CRISPR Technology Evolution
/products/press/blogDomain Ages
CRISPR PLATFORM TRACKER ════════════════════════════════════════════════════════ crisprtx.com — CRISPR Therapeutics /products: CTX001 (Casgevy) — First CRISPR therapy approved /press: In vivo CRISPR programs advancing (CTX310, CTX320) SIGNAL: Platform validated — next-gen in vivo approach editasmedicine.com — Editas Medicine /products: EDIT-301 — next-gen sickle cell/beta-thal /blog: Novel AsCas12a editing with improved efficiency SIGNAL: Differentiation from Casgevy needed beamtx.com — Base Editing /products: BEAM-101 (SCD), BEAM-201 (T-ALL), BEAM-302 (AATD) /press: 3 clinical programs — most advanced base editing pipeline SIGNAL: Base editing gaining clinical traction

3NGS Technology Assessment

AI agent monitors next-generation sequencing company domains to track platform launches, throughput improvements, cost reductions, and new applications — informing sequencing technology investment decisions.

1
Track NGS Platform Evolution
/products/investors/pressIAB Categories
NGS TECHNOLOGY LANDSCAPE ════════════════════════════════════════════════════════ illumina.com — Short-Read Sequencing /products: NovaSeq X Plus — $200 whole genome achieved /investors: Revenue $4.5B | Install base 22,000+ SIGNAL: Cost curve accelerating — new applications unlocked nanoporetech.com — Oxford Nanopore /products: PromethION 2 — desktop long-read sequencing /press: Q-score now exceeds Q30 — accuracy parity SIGNAL: Long-read accuracy breakthrough — competitive threat pacb.com — PacBio /products: Revio system — HiFi long reads at scale /investors: Revenue $200M — growth slowing SIGNAL: Squeezed between Illumina and ONT

4Gene Editing IP Landscape

AI agent monitors patent filings and IP developments across gene editing companies to map freedom-to-operate, identify licensing opportunities, and track IP disputes.

1
Map Gene Editing IP
/legal/press/investorsOpenPageRank
GENE EDITING IP LANDSCAPE ════════════════════════════════════════════════════════ broadinstitute.org /legal: CRISPR-Cas9 patents — broad eukaryotic claims /press: Licensing framework updated — 250+ licensees SIGNAL: Foundation IP — required license for Cas9 therapeutics cariboubio.com /legal: chRDNA technology patents — 14 patent families /press: Novel CRISPR-hybrid approach avoids Broad IP SIGNAL: Potential IP workaround — evaluate license terms IP DISPUTES ACTIVE: Base editing foundational patents: 3 interference proceedings Prime editing IP ownership: Pending USPTO decision

5Cell Therapy Manufacturing

AI agent monitors cell therapy CDMO and manufacturing domains to track capacity expansion, process innovations, and cost reduction signals — informing manufacturing strategy for cell and gene therapies.

1
Track Cell Therapy Manufacturing
/products/press/careersCountries
CELL THERAPY MANUFACTURING INTELLIGENCE ════════════════════════════════════════════════════════ lonza.com — Cell & Gene CDMO /products: Cocoon automated manufacturing platform /press: $500M facility expansion in Houston /careers: +55% manufacturing scientist postings SIGNAL: Major capacity expansion — evaluate partnership catalent.com — Cell Therapy Manufacturing /products: GPEx cell line development platform /press: FDA Form 483 at gene therapy facility SIGNAL: Quality concern — monitor remediation progress MANUFACTURING CAPACITY OUTLOOK: Global CGT manufacturing capacity: 60% utilization New facilities coming online 2026-27: 14 announced Vein-to-vein time trend: Decreasing from 28 to 18 days avg

6Base & Prime Editing Advances

AI agent tracks next-generation gene editing modalities including base editing and prime editing to monitor clinical progress, platform improvements, and competitive differentiation from traditional CRISPR approaches.

1
Monitor Next-Gen Editing Platforms
/products/press/blogDomain Ages
NEXT-GEN EDITING PLATFORM TRACKER ════════════════════════════════════════════════════════ primemedicine.com — Prime Editing /products: Prime editing — search-and-replace for DNA /press: IND-enabling studies for CGDP Domain Age: 1,400 days | PageRank: 4.8 SIGNAL: First prime editing IND expected 2026 vervetx.com — In Vivo Base Editing /products: VERVE-102 — next-gen LNP + base editor /blog: Coronary heart disease — permanent PCSK9 knockdown SIGNAL: Cardiovascular base editing approaching pivotal chroma-medicine.com — Epigenetic Editing /products: Gene silencing without DNA breaks /press: $135M Series B raised SIGNAL: Epigenetic editing — novel approach gaining traction

7Epigenetic Therapy Tracking

AI agent monitors epigenetic therapy companies to track developments in DNA methylation, histone modification, and chromatin remodeling therapies — an emerging class of precision medicines.

1
Track Epigenetic Medicine Landscape
/products/investors/pressIAB Categories
EPIGENETIC THERAPY INTELLIGENCE ════════════════════════════════════════════════════════ constellationpharma.com /products: Pelabresib (BET inhibitor) — Phase 3 myelofibrosis /investors: MANIFEST-2 topline: SVR35 rate 65.9% vs 35.2% SIGNAL: First-in-class BET inhibitor — NDA filing 2026 epicypher.com — Epigenetics Tools /products: CUTANA CUT&RUN — chromatin profiling kits /blog: New histone PTM antibodies validated SIGNAL: Research tools improving — more drug targets expected EPIGENETIC PIPELINE: BET inhibitors in clinic: 8 programs EZH2 inhibitors approved: 1 (tazemetostat) DNMT inhibitors in development: 4 next-gen compounds

8Spatial Genomics Innovation

AI agent monitors spatial biology and spatial genomics companies to track technology platforms, new applications, and adoption trends — informing research tool investments and partnership decisions.

1
Track Spatial Genomics Technology
/products/press/case-studiesOpenPageRank
SPATIAL GENOMICS TECHNOLOGY LANDSCAPE ════════════════════════════════════════════════════════ 10xgenomics.com — Visium / Xenium /products: Xenium In Situ — 5,000 gene spatial transcriptomics /case-studies: Tumor microenvironment mapping at single-cell /press: Xenium Prime launched — whole transcriptome spatial SIGNAL: Market leader — platform expanding rapidly nanostring.com — CosMx/GeoMx /products: CosMx SMI — subcellular spatial multi-omics /investors: Acquired by Bruker — integration ongoing SIGNAL: Technology strong but corporate transition risk vizgen.com — MERFISH Platform /products: MERSCOPE — single-molecule FISH imaging /press: 1,000+ gene panels now available SIGNAL: Competitive platform — evaluate for drug discovery

9Multiomics Integration

AI agent monitors multiomics technology companies to track platform integration, data analysis tools, and clinical applications combining genomics, proteomics, metabolomics, and transcriptomics.

1
Track Multiomics Platform Development
/products/partners/pressIAB Categories
MULTIOMICS PLATFORM INTELLIGENCE ════════════════════════════════════════════════════════ somalogic.com — Proteomics /products: SomaScan — 11,000 protein assay /partners: UK Biobank, AstraZeneca, Regeneron SIGNAL: Proteomic drug target discovery gaining adoption olink.com — Proximity Extension Assay /products: Olink Explore HT — 5,400 protein panel /press: Acquired by Thermo Fisher — broader distribution SIGNAL: Integration with Thermo Fisher accelerates adoption metabolon.com — Metabolomics /products: Global metabolomics — 1,200+ metabolites /case-studies: Biomarker discovery for 40+ pharma partners SIGNAL: Metabolomics maturing as clinical tool

10Genomics R&D Dashboard

AI agent synthesizes all genomics and CRISPR intelligence into an executive dashboard — providing leadership with real-time visibility into technology evolution, competitive dynamics, and strategic opportunities.

1
Generate Genomics Intelligence Dashboard
/products/investors/pressOpenPageRankIAB Categories
GENOMICS R&D DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ TECHNOLOGY LANDSCAPE: Gene editing companies tracked: 280 CRISPR clinical programs: 42 active globally NGS cost per genome: $200 (down from $600 in 2023) IP LANDSCAPE: Active patent disputes: 3 major proceedings New gene editing patents filed: 180+ this quarter MANUFACTURING: CGT facilities expanding: 14 new builds announced Capacity utilization: 60% — some overcapacity risk
2
Generate Genomics Report

Genomics & CRISPR Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Gene therapy companies tracked: 280 domains CRISPR programs in clinic: 42 globally NGS platforms assessed: 12 technologies Spatial genomics tools: 8 platforms evaluated KEY INSIGHTS Base editing reaching clinical inflection point — 3 programs in clinic. NGS cost approaching $200/genome enabling population-scale studies. Spatial genomics market growing 45% YoY — evaluate platform investment. Gene therapy manufacturing expanding but quality remains critical focus. Epigenetic editing emerging as complementary approach to CRISPR.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.